How to Buy 10x Genomics Stock
10x Genomics Inc
10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
10x Genomics stock last closed at $52.88, up 3.2% from the previous day, and has increased 11.68% in one year. It has overperformed other stocks in the Health Information Services industry by 0.32 percentage points. 10x Genomics stock is currently +122.09% from its 52-week low of $23.81, and -9.29% from its 52-week high of $58.30.
At the moment, there are 116.19M shares of TXG outstanding. The market cap of TXG is $6.14B. In the last 24 hours, 719,259 TXG shares were traded.
How to Buy 10x Genomics Stock
Wondering how to invest in 10x Genomics stock? Here's how.
- Decide where to buy 10x Genomics stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you choose where to buy 10x Genomics stock.
- Open a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Select your method of payment and add your info.
- Research 10x Genomics stock: The 10x Genomics ticker symbol is TXG. Is 10x Genomics stock a good investment? Should you buy shares of TXG? How do TXG's underlying business fundamentals look? Do top analysts think 10x Genomics is a good buy? Why has TXG's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if TXG is a good stock to buy).
- Make your TXG purchase: Decide if you will purchase TXG shares at the current market price or use a limit order to buy TXG stock at a given price.
- Track your TXG position: Create a watchlist to monitor your new investment in 10x Genomics stock.
Step 1: Decide where to buy 10x Genomics stock
You will need an online brokerage account to access the NASDAQ market and buy TXG shares.
Our favorite brokerage: eToro
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Industrials, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro today.
Open eToro AccountStep 2: Open a brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you can buy TXG stock today.
How to Open a New Investment Account on eToro
- Click here to get started.
- Provide your personal details to open your new brokerage account.
- Submit your info by hitting the "Create Account" button.
Step 3: Deposit funds into your investment account
Now that you've filled out your info on stock market apps, you can securely and quickly fund your account:
Watch the walkthrough below for more details depositing funds into your brokerage account.
Step 4: Research 10x Genomics stock
Once you have selected the best place to buy 10x Genomics stock, it's important to research their stock prior to investing, so you can understand the risk as well as the upside.
10x Genomics shares quick numbers
10x Genomics Overview
WallStreetZen was built to help everyday investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on TXG's stock page.
Is TXG stock overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge TXG's intrinsic value.
Using relative valuations metrics:
- TXG may be overvalued based on its P/B ratio of 7.66x, relative to Health Information Services industry P/B ratio of 3.29x
You can do more valuation research on TXG's stock here.
TXG Financial Summary
Signs that TXG is financially healthy:
- TXG has a low debt to equity ratio of 0.26.
- TXG has $425.76M in cash and short term investments. This is enough to cover its annual cash burn of $125.01M.
- TXG has cash burn of 125013000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the TXG balance sheet.
- There are more short-term assets than long-term liabilities on the TXG balance sheet.
Signs that TXG is not financially healthy:
- TXG profit margin has gone down from -17.8% to -32.5% in the past year.
Is 10x Genomics stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 8 sell side analysts who research TXG, the consensus analyst rating on TXG is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
Latest TXG Analyst Ratings
Mason Carrico, a bottom 4% analyst from Stephens & Co. reiterates TXG with a strong buy rating and maintains their TXG price target from $65.00 to $65.00, on May 18, 2023.
Luke Sergott, a bottom 2% analyst from Barclays initiates coverage on TXG with a strong buy rating and announces their TXG price target of $65.00, on May 10, 2023.
Daniel Arias, a top 9% analyst from Stifel Nicolaus maintains TXG with a strong buy rating and raises their TXG price target from $57.00 to $68.00, on May 4, 2023.
Maintaining his Strong Buy rating, Arias raised his price target on 10x Genomics, Inc. by 19.3% following the release of the company's Q1 2023 earnings report on 2023/05/03.
10x Genomics' kicked off FY 2023 with a "solid" print, the analyst summarized.
The revenue beat was "largely expected," but management's guidance raise did not meet analysts' expectations, Arias detailed.
While China was, for the most part, down, the analyst argued that, overall, the set-up for 10x Genomics remains positive in terms of further upside."
The stock is up 41.8% YTD against the S&P 500's 7.3% gain.
For Q1 2023, 10x Genomics reported:
- Loss per share of $0.44, which missed the Zacks Consensus Estimate and Q1 2022, both $(0.38).
- Revenue of $134.29M, which beat the Zacks Consensus Estimate by 4.22% and Q1 2022's $114.5M by 17.3%.
- Gross margin of 73%, down from Q1 2022's 78%.
For FY 2023, management guided:
- Revenue of $590M to $610M, representing 14% to 18% growth Y/Y, up from the previously guided $580M to $600M.
Co-founder & CEO Serge Saxonov commented: "We are proud of our solid start to the year, fueled by strong performance across our spatial portfolio and a return to double-digit growth in single-cell consumables.
"We are energized by the momentum and traction we're seeing with Xenium* in its first full quarter of launch; the overwhelmingly positive feedback from our early customers reinforces our belief that Xenium is the best In Situ platform on the market."
* From here: Xenium is an instrument that spatially profiles genes and proteins at subcellular resolution. Xenium enables subcellular mapping of hundreds of RNA targets, generating high-quality data with high sensitivity and specificity to reveal insights into cellular structure and function."
Dan Brennan, a top 16% analyst from TD Cowen maintains TXG with a buy rating and raises their TXG price target from $62.00 to $66.00, on May 4, 2023.
Kyle Mikson, a bottom 3% analyst from Canaccord Genuity maintains TXG with a strong buy rating and raises their TXG price target from $58.00 to $65.00, on May 4, 2023.
You can dig deeper into what analysts are forecasting on the 10x Genomics stock forecast page.
TXG Technical Indicators
TXG Growth Numbers
Last year, TXG revenue was $536.20M. In the last 3 year, TXG's revenue has grown by 100.97% per year. This was faster than the Health Information Services industry average of 48.97%.
You can research TXG's earnings and revenue performance here.
Who is buying/selling TXG?
In the past year, executives and large shareholders at TXG have bought more shares than they have sold.
Benjamin J. Hindson, President and Chief Scientific Officer of TXG, was the latest TXG insider to sell. They sold $34,082.14 worth of TXG stock on May 23, 2023.
Get more info about who owns TXG stock here.
Does TXG stock generate passive income?
No, 10x Genomics doesn't provide an income stream by paying out dividends.
What do other investors have to say about TXG?
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your TXG purchase
You have two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually fine for most investors. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price, use a limit order.
Click the Open Trade button and eToro will execute the order.
If you want more help buying stocks on eToro, click the how to video below:
Step 6: Track your TXG position
Now that you own some shares in TXG, you'll want to keep up with your shares.
Start a watchlist to get alerted to the latest events about your TXG stock.
TXG Feed
How to Buy Stock in 10x Genomics
To summarize, here are the 6 steps to buy stock in 10x Genomics:
- Decide where to buy 10x Genomics stock
- Open a brokerage account
- Deposit funds into your investment account
- Research 10x Genomics stock
- Make your TXG purchase
- Track your TXG position
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get notifications regarding your new investment in 10x Genomics, click below.
Other "How To" Guides You May Find Useful
FAQ
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.